Cediranib maleate is primarily used in the treatment of various types of cancer, particularly as a targeted therapy. It functions as a potent inhibitor of vascular endothelial growth factor (VEGF) receptors, which play a critical role in angiogenesis—the process by which tumors develop new blood vessels to support their growth. By blocking these receptors, it helps to cut off the blood supply to tumors, thereby inhibiting their progression. This compound has shown efficacy in clinical trials for cancers such as ovarian cancer, colorectal cancer, and non-small cell lung cancer. It is often used in combination with other chemotherapeutic agents or radiotherapy to enhance its therapeutic effects. Additionally, cediranib maleate is being investigated for its potential in treating other malignancies and as part of personalized medicine approaches based on specific genetic markers in tumors. Its application continues to evolve as researchers explore its full potential in oncology.